Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in a Swiss registry.
Enriqueta Vallejo-YagüeTheresa BurkardAxel FinckhAndrea Michelle Burdennull nullPublished in: BMJ open (2024)
No differences in DAS28-remission were found between the study drugs and adalimumab as first biologic in patients with RA, independently of the BMI cohort. We did not find evidence that treatment with abatacept increased the likelihood of remission compared with adalimumab among obese patients with RA.
Keyphrases
- rheumatoid arthritis
- disease activity
- body mass index
- rheumatoid arthritis patients
- juvenile idiopathic arthritis
- ankylosing spondylitis
- interstitial lung disease
- weight gain
- systemic lupus erythematosus
- metabolic syndrome
- weight loss
- adipose tissue
- type diabetes
- ulcerative colitis
- obese patients
- combination therapy
- bariatric surgery
- drug induced
- hidradenitis suppurativa
- smoking cessation